Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$666000.0.

  • Serina Therapeutics' Change in Accured Expenses fell 30429.45% to -$666000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$30000.0, marking a year-over-year decrease of 15555.56%. This contributed to the annual value of $400000.0 for FY2024, which is 38571.43% up from last year.
  • As of Q3 2025, Serina Therapeutics' Change in Accured Expenses stood at -$666000.0, which was down 30429.45% from $756000.0 recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Change in Accured Expenses registered a high of $756000.0 during Q2 2025, and its lowest value of -$666000.0 during Q3 2025.
  • Its 5-year average for Change in Accured Expenses is -$35052.6, with a median of -$50000.0 in 2023.
  • Over the last 5 years, Serina Therapeutics' Change in Accured Expenses had its largest YoY gain of 44358.97% in 2024, and its largest YoY loss of 109400.0% in 2024.
  • Over the past 5 years, Serina Therapeutics' Change in Accured Expenses (Quarter) stood at -$153000.0 in 2021, then soared by 258.17% to $242000.0 in 2022, then tumbled by 132.23% to -$78000.0 in 2023, then soared by 443.59% to $268000.0 in 2024, then plummeted by 348.51% to -$666000.0 in 2025.
  • Its Change in Accured Expenses stands at -$666000.0 for Q3 2025, versus $756000.0 for Q2 2025 and -$388000.0 for Q1 2025.